---
title: Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
date: '2024-05-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38820078/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240601181228&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In this trial comparing asciminib with investigator-selected
  TKIs and imatinib, asciminib showed superior efficacy and a favorable safety profile
  in patients with newly diagnosed chronic-phase CML. Direct comparison between asciminib
  and second-generation TKIs was not a primary objective. (Funded by Novartis; ASC4FIRST
  ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In this trial comparing asciminib with investigator-selected TKIs and imatinib, asciminib showed superior efficacy and a favorable safety profile in patients with newly diagnosed chronic-phase CML. Direct comparison between asciminib and second-generation TKIs was not a primary objective. (Funded by Novartis; ASC4FIRST ClinicalTrials.gov number, ...